Introduction en Bourse de Quantum Genomics sur Alternext Paris


Paris – 10 April 2014 EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1], today congratulated Quantum Genomics, a biopharmaceutical research company developing new therapies for cardiovascular disease, on its transfer from the Free Market to Alternext in Paris following a €3.4 million private placement.

Quantum Genomics is a biopharmaceutical company that develops new therapies for unmet medical needs in the treatment of cardiovascular disease, in particular high blood pressure and heart failure. The company has built a balanced portfolio of candidate drugs using a new therapeutic approach based on Brain Aminopeptidase A Inhibition, developed through over 20 years of research at the Collège de France, INSERM and CNRS.

Quantum Genomics (new ticker symbol: ALGTCL) was listed through the admission to trading on Alternext Paris of 4,747,403 shares making up the company’s equity, including 637,334 newly issued shares resulting from a private placement of around €3.4 million with qualified investors at the unit price of €5.35.  

“We congratulate Quantum Genomics on the milestone represented by its successful listing on Alternext, Euronext’s self-regulated market,”said Eric Forest, Chairman and CEO of EnterNext. “This transfer will boost Quantum Genomics’ visibility with larger number of investors. EnterNext will continue to accompany the company as it works to achieve its aims.”

Lionel Ségard, Chairman and CEO of Quantum Genomics, added: “This capital increase is part of our long-term goal of building a shareholder base with investors prepared to participate in Quantum Genomics’ growth and the financing of our research programmes. In the short term, funds raised will enable us to recruit more experts and start clinical phase II testing of our most advanced product for fighting high blood pressure.”

[1]Small and medium-sized entreprises

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.